Drug Profile
ETBX 051
Alternative Names: Ad5 brachyury vaccine; Adenoviral brachyury vaccine - Etubics; ETBX-051; Universal influenza vaccine - EtubicsLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Etubics Corporation
- Developer Etubics Corporation; ImmunityBio; National Cancer Institute (USA)
- Class Antineoplastics; Cancer vaccines; Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Colorectal cancer; Pancreatic cancer; Triple negative breast cancer
- No development reported Influenza virus infections; Prostate cancer; Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (SC)
- 28 May 2021 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Metastatic disease) in USA (SC)
- 09 Mar 2021 National Cancer Institute completes a phase I trial in Prostate cancer (Metastatic disease; Combination therapy) in USA (SC) (NCT03481816)